Sanochemia acquires majority shareholding in AlcaSynn
In the course of a venture capital transaction, Sanochemia Pharmazeutika AG has acquired a 60% holding in Innsbruck-based AlcaSynn Pharmaceuticals GmbH. Through its stake in this company, founded in 2002 by Prof. Dr. Helmut Schmidhammer and Dr. Johannes Schütz, Sanochemia has secured access to a broad technological base and extensive developmental resources in the fields of pain management and CNS.
In cooperation with leading pharmaceutical players, AlcaSynn develops drugs on the basis of synthetic morphinan derivatives with a marked pharmacological profile for the treatment of pain, inflammation, Parkinson's and Alzheimer's. The company is headed by Dr. Peter Kayatz (CEO) and Dr. Mariana Spetea (CSO) and currently holds a patent portfolio consisting of 13 awarded patents and a further 26 patents pending.
The leading product candidate, AS006, is a strong, peripherally-acting painkiller (100 times stronger than morphine) which does not exhibit the adverse side effects characteristic of other opiates including respiratory depression, drowsiness and potential addiction. AS006 is currently in pre-clinical testing with clinical trials scheduled to begin in 2008.
Sanochemia's shareholding in AlcaSynn Pharmaceuticals GmbH represents a major strategic addition to its potential as a provider of specialty pharmaceuticals in its existing development segments. Key for Sanochemia is the synergy potential offered by utilising its synthesis plant located in Neufeld, Austria.
Most read news
Topics
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.

Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Last viewed contents
Stephen_Moulton_Babcock

INERATEC Raises $129 Million Led by Piva Capital to Usher in the Next Era of Sustainable Mobility - Investment to Accelerate the Production and Commercialization of Carbon-Neutral e-Fuel
Using hydrogen to enhance lithium ion batteries - Lithium ion batteries operate longer and faster when treated with hydrogen.

Mimicking biological enzymes may be key to hydrogen fuel production - An ancient enzyme may be crucial in the world’s push toward a renewable energy economy

Reduced ignition propensity requirement may cause changes to cigarette smoke chemistry

Artkim Group - Istanbul, Turkey

200 mio. € investment in green hydrogen pioneer Hy2gen AG - Capital will be deployed on e-fuels to decarbonise industry and transportation sectors
![Potential for a green energy economy based on hydrogen - First Characterization of a Sensory [FeFe] Hydrogenase](https://img.chemie.de/Portal/News/110728_f0g-fwqjA.jpg?tr=n-xzoom)